Dawn N Waterhouse

Summary

Affiliation: British Columbia
Country: Canada

Publications

  1. ncbi QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outc
    Jessica Kalra
    Advanced Therapeutics, BC Cancer Agency, Vancouver, British Columbia, Canada
    Breast Cancer Res 11:R25. 2009
  2. ncbi Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine
    Maite Verreault
    Experimental Therapeutics, British Columbia Cancer Agency, 675 West 10thAvenue, Vancouver, BC V5Z 1L3, Canada
    BMC Cancer 11:124. 2011
  3. ncbi A novel combination of Chinese medicines to treat advanced cancers and lymphomas in rats
    Dawn N Waterhouse
    Department of Advanced Therapeutics, BC Cancer Research Centre, 675 West 10th Avenue, Vancouver, BC V5Z 1L3, Canada
    Chin Med 4:22. 2009
  4. ncbi Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers
    D N Waterhouse
    Investigational Drug Program, BC Cancer Agency, 675 West 10th Avenue, Vancouver, BC, V5Z 1L3, Canada
    Curr Cancer Drug Targets 6:455-89. 2006
  5. ncbi Trastuzumab and liposomal Doxorubicin in the treatment of mcf-7 xenograft tumor-bearing mice: combination does not affect drug serum levels
    Dawn N Waterhouse
    BC Cancer Agency, USA
    Pharm Res 22:915-22. 2005
  6. ncbi Retraction: a novel combination of Chinese medicines to treat advanced cancers and lymphomas tested in rats
    Dawn N Waterhouse
    Department of Advanced Therapeutics, BC Cancer Research Centre, 675 West 10thAvenue, Vancouver, BC V5Z 1L3, Canada
    Chin Med 5:10. 2010
  7. ncbi Pharmacodynamic behavior of liposomal antisense oligonucleotides targeting Her-2/neu and vascular endothelial growth factor in an ascitic MDA435/LCC6 human breast cancer model
    Dawn N Waterhouse
    British Columbia Cancer Research Centre, Department of Advanced Therapeutics, Vancouver, BC, Canada
    Cancer Biol Ther 3:197-204. 2004
  8. ncbi HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization
    Wieslawa H Dragowska
    Department of Advanced Therapeutics, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, Canada V5Z 4E6
    Mol Cancer Res 2:606-19. 2004
  9. ncbi Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK)
    Lincoln A Edwards
    Department of Advanced Therapeutics, BC Cancer Agency, Vancouver, British Columbia, Canada
    Mol Cancer Ther 7:59-70. 2008
  10. ncbi Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model
    Dawn N Waterhouse
    British Columbia Cancer Research Centre, Department of Advanced Therapeutics, Vancouver, Canada
    J Exp Ther Oncol 3:261-71. 2003

Detail Information

Publications14

  1. ncbi QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outc
    Jessica Kalra
    Advanced Therapeutics, BC Cancer Agency, Vancouver, British Columbia, Canada
    Breast Cancer Res 11:R25. 2009
    ..The purpose of this study was to investigate the therapeutic potential of the ILK small molecule inhibitor, QLT0267 (267), alone or in combination with chemotherapies commonly used to treat breast cancer patients...
  2. ncbi Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine
    Maite Verreault
    Experimental Therapeutics, British Columbia Cancer Agency, 675 West 10thAvenue, Vancouver, BC V5Z 1L3, Canada
    BMC Cancer 11:124. 2011
    ..The present study evaluates how treatment with liposomal formulation of irinotecan (Irinophore C™), and other liposomal anticancer drugs, influence the tumor vasculature of GBM models grown either orthotopically or subcutaneously...
  3. ncbi A novel combination of Chinese medicines to treat advanced cancers and lymphomas in rats
    Dawn N Waterhouse
    Department of Advanced Therapeutics, BC Cancer Research Centre, 675 West 10th Avenue, Vancouver, BC V5Z 1L3, Canada
    Chin Med 4:22. 2009
    ..CONCLUSION: OMN54 was found to be well tolerated in rat models. OMN54 did not cause any microscopic, anatomic or pathologic changes in exposed animals at the concentrations and under the conditions employed in this study...
  4. ncbi Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers
    D N Waterhouse
    Investigational Drug Program, BC Cancer Agency, 675 West 10th Avenue, Vancouver, BC, V5Z 1L3, Canada
    Curr Cancer Drug Targets 6:455-89. 2006
    ....
  5. ncbi Trastuzumab and liposomal Doxorubicin in the treatment of mcf-7 xenograft tumor-bearing mice: combination does not affect drug serum levels
    Dawn N Waterhouse
    BC Cancer Agency, USA
    Pharm Res 22:915-22. 2005
    ....
  6. ncbi Retraction: a novel combination of Chinese medicines to treat advanced cancers and lymphomas tested in rats
    Dawn N Waterhouse
    Department of Advanced Therapeutics, BC Cancer Research Centre, 675 West 10thAvenue, Vancouver, BC V5Z 1L3, Canada
    Chin Med 5:10. 2010
    ..In the light of this situation, BioMed Central regrets that this article is no longer available. The author apologises to all parties for the inconvenience...
  7. ncbi Pharmacodynamic behavior of liposomal antisense oligonucleotides targeting Her-2/neu and vascular endothelial growth factor in an ascitic MDA435/LCC6 human breast cancer model
    Dawn N Waterhouse
    British Columbia Cancer Research Centre, Department of Advanced Therapeutics, Vancouver, BC, Canada
    Cancer Biol Ther 3:197-204. 2004
    ..Tissue distribution studies of both free and liposome encapsulated ASO indicated that ASO distribution was dictated primarily by the liposomal carrier when administered in liposomal form...
  8. ncbi HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization
    Wieslawa H Dragowska
    Department of Advanced Therapeutics, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, Canada V5Z 4E6
    Mol Cancer Res 2:606-19. 2004
    ..These results suggest that HER-2/neu overexpression may be linked with overall increased tumor viability and a significant increase in the population of viable hypoxic cells, which is not due to differences in tumor vascularization...
  9. ncbi Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK)
    Lincoln A Edwards
    Department of Advanced Therapeutics, BC Cancer Agency, Vancouver, British Columbia, Canada
    Mol Cancer Ther 7:59-70. 2008
    ..The therapeutic effects of a selected ILK inhibitor (QLT0267) should be determined in the clinic in cancers that exhibit dysregulated ILK, such as PTEN-null glioblastomas...
  10. ncbi Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model
    Dawn N Waterhouse
    British Columbia Cancer Research Centre, Department of Advanced Therapeutics, Vancouver, Canada
    J Exp Ther Oncol 3:261-71. 2003
    ....
  11. ncbi Lipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy
    Dawn N Waterhouse
    BC Cancer Agency, Department of Experimental Therapeutics, 675 West 10th Avenue, Vancouver BC Canada, V5Z 1L3
    Nanomedicine (Lond) 6:1645-54. 2011
    ....
  12. ncbi Preparation, characterization, and biological analysis of liposomal formulations of vincristine
    Dawn N Waterhouse
    Department of Advanced Therapeutics, British Columbia Cancer Agency, British Columbia, Canada
    Methods Enzymol 391:40-57. 2005
    ..and key biological endpoints (circulation lifetime, bioavailability, efficacy measurements) important to the development of a formulation of vincristine with enhanced therapeutic properties...
  13. ncbi The liposomal formulation of doxorubicin
    Sheela A Abraham
    Cambridge Institute for Medical Research, Addenbrooke's Hospital, Cambridge, UK
    Methods Enzymol 391:71-97. 2005
    ....
  14. ncbi Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs
    Gigi N C Chiu
    Department of Pharmacy, Faculty of Science, National University of Singapore, 18 Science Drive 4, Singapore 117543, Singapore
    Mol Cancer Ther 6:844-55. 2007
    ..The data presented here showed the potential of liposome technology to enhance the therapeutic effect of antibodies via a mechanism that modulates cell survival through clustering of the target/antibody complex...